11.29.16
Accinov and Biodextris have signed an agreement through which the two companies will work together to co-promote their complementary services to clients in Europe, North America and beyond.
Lyon, France-based Accinov will be able to present clients to Biodextris' process development, analytical development and cGMP QC testing services. Biodextris, of Laval, Canada, can in turn introduce clients to Accinov's flexible, ready-to-use cGMP biomanufacturing environment and associated quality assurance services.
"We are excited to enter this agreement with Accinov, who are pioneering a biomanufacturing model unique in the pharmaceutical and biotechnology industries," said Joseph Zimmermann, president and chief executive officer, Biodextris. "This strategic collaboration reflects our commitment to providing a full-spectrum service offering and broadening the competitive advantage customers realize working with our organizations.”
"The Biodextris team's history of advancing vaccine and biologic products to the clinic and the Accinov team's expertise are complementary and self-reinforcing," said André Dupont, president, Accinov. "Together we establish a wholly flexible solution for the development and GMP manufacturing of new biopharmaceuticals."
Lyon, France-based Accinov will be able to present clients to Biodextris' process development, analytical development and cGMP QC testing services. Biodextris, of Laval, Canada, can in turn introduce clients to Accinov's flexible, ready-to-use cGMP biomanufacturing environment and associated quality assurance services.
"We are excited to enter this agreement with Accinov, who are pioneering a biomanufacturing model unique in the pharmaceutical and biotechnology industries," said Joseph Zimmermann, president and chief executive officer, Biodextris. "This strategic collaboration reflects our commitment to providing a full-spectrum service offering and broadening the competitive advantage customers realize working with our organizations.”
"The Biodextris team's history of advancing vaccine and biologic products to the clinic and the Accinov team's expertise are complementary and self-reinforcing," said André Dupont, president, Accinov. "Together we establish a wholly flexible solution for the development and GMP manufacturing of new biopharmaceuticals."